An observational study in Esophageal Cancer and Esophagectomy, sponsored by Shanghai Chest Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Shanghai Chest Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Esophageal Neoplasms by Shanghai Chest Hospital — 7 open to participants now, 8 under way, 1 of them phase 3. Esophageal Neoplasms · Shanghai Chest Hospital.
Among the 13 studies in Esophageal Neoplasms by Shanghai Chest Hospital, this one is one of 2 that started in 2025, is one of 4 observational ones, and was the 13th registered.
1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.
Browse Esophageal Neoplasms studies →7 of the 13 studies in Esophageal Neoplasms by Shanghai Chest Hospital are open now, in 1 country. Recruiting first, the newest first:
Shanghai Chest Hospital · Sites in China
Ages 76+
Shanghai Chest Hospital · Sites in China
Ages 18–80
Shanghai Chest Hospital · Sites in China
Ages 18+
Shanghai Chest Hospital · Sites in China
Ages 18–75
Shanghai Chest Hospital · Sites in China
Ages 18–75
By country, each count listing its studies:
Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,500 is above the median of 200 across 433 observational studies indexed under Esophageal Neoplasms.
Median enrollment 60 across the 9 interventional studies, 225 across the 4 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Shanghai Chest Hospital is the lead sponsor of 198 studies on the registry; 99 are open to participants now.
1 of the studies in Esophageal Neoplasms by Shanghai Chest Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05978193Shanghai Chest HospitalRadiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Esophageal Neoplasms by Shanghai Chest Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A prospective cohort of patients who received esophagectomy for esophageal cancer in participating centers.
A prospective cohort of patients who received esophagectomy for esophageal cancer in participating centers.
Patients received esophagectomy for esophageal cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
esophagectomy
Overal survival
Time frame: From the date of enrollment until the date of death or loss of follow-up, assessed up to 10 years. Follow-up is scheduled every 3 months in the first 2 years. Every 6 months from the 2nd to the 5th year. Then once a year. Until death or loss of follow.
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2025 to primary completion in Mar 2026, 8 months.
Of 152 non-industry observational studies under Esophageal Neoplasms, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 252. This study's 8 months is below that.
Counting every sponsor, half of 174 studies reached it within 64 months; a quarter within 33 and three quarters within 252.
Completion moved once since we started tracking on Sep 25, 2026: Mar 2026 → Dec 2026, on Nov 13, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.